Table 2.

Changes from baseline in body weight, thirst index, fluid intake, AVP, renin, and aldosterone at the end of the double-blind perioda

ParametersPlacebo (n = 8)Satavaptan
25 mg (n = 14)50 mg (n = 12)
Body weight (kg)
    baseline (mean ± SD)60.6 ± 9.959.5 ± 12.456.9 ± 12.5
    change from baseline (mean ± SD)−1.2 ± 2.0−0.4 ± 1.4−1.3 ± 1.7
    P value (versus placebo)0.2980.930
Thirst index (mm)
    baseline (mean ± SD)51 ± 2550 ± 1456 ± 13
    change from baseline (mean ± SD)−3 ± 244 ± 176 ± 30
    P value (versus placebo)0.5340.466
Fluid intake (ml/24 h)
    baseline (mean ± SD)1570 ± 6121558 ± 5511539 ± 925
    change from baseline (mean ± SD)−211 ± 550−113 ± 706275 ± 926
    P value (versus placebo)0.7760.185
AVP (ng/L)
    baseline (mean ± SD)1.5 ± 1.91.4 ± 2.23.6 ± 9.1
    change from baseline (mean ± SD)−0.7 ± 1.31.0 ± 1.72.6 ± 6.7
    P value (versus placebo)0.3910.100
Renin (ng/ml per h)
    baseline (mean ± SD)0.6 ± 0.60.9 ± 1.11.7 ± 4.4
    change from baseline (mean ± SD)0.4 ± 0.70.3 ± 1.40.5 ± 3.1
    P value (versus placebo)0.9660.932
Aldosterone (ng/L)
    baseline (mean ± SD)144 ± 15893 ± 7965 ± 66
    change from baseline (mean ± SD)−31 ± 5414 ± 145−2 ± 68
    P value (versus placebo)0.3440.554
  • a AVP, arginine vasopressin.